EGFR and neoplasm: Other groups have developed bsAb-based molecules that simultaneously target two tumour-associated antigens such as EGFR and insulin growth factor receptor (IGFR) (Lu et al, 2005) or carcinoembryonic antigen (CEA) and ErbB2 (Dorvillius et al, 2002).